•  
  •  
 

Subject Area

Ophthalmology

Article Type

Original Study

Abstract

Objectives The objective of this study was to study the role and the prognostic value of urokinase-type plasminogen activator receptor (uPAR) (CD87) expression in patients with de-novo acute myeloid leukemia (AML). Background The physiological function of the uPAR (CD87) is concerned in various biological processes and signal transduction such as cancer metastasis, angiogenesis, cell migration, and wound healing. The uPAR is expressed in most solid cancer and in several hematological malignancies including myeloproliferative disease, acute leukemia (AML, acute lymphocytic leukemia), and multiple myeloma. Patients and methods This study was conducted on 52 newly diagnosed patients with AML and 20 age-matched and sex-matched healthy individuals as a control group. Full history taking, clinical examination, and laboratory investigations were done for all patients. Expression of CD87 was evaluated by flow cytometric analysis. Results Positive CD87 expression (CD87+) was significantly higher in patients with AML than in healthy individuals. The highest incidence of CD87+ was found in acute myelomonocytic leukemia and acute monoblastic leukemia (M4/M5). High CD87+ expression in patients with AML predicted poor response to therapy, poor outcome, and shorter overall survival rate. Conclusion The high expression of CD87 displays a negative prognostic effect on patients with AML regarding outcome, survival rate, and response to chemotherapy. However, more studies are required to elucidate its role as a target therapy for those patients as its expression is highly restricted to tumor cells.

Download

Share

COinS